A new covalent organic framework uses boron and phosphorus to make complex connections. This new COF is composed of repeating borophosphonate cubes linked at the vertices. O = red; B = pink; P...
The College is pleased to announce C. Judson King's A History of Berkeley Chemical Engineering: Pairing Engineering and Science is now available on eScholarship, Berkeley's flagship scholarly repository, and as a print book from...
In the modern age of pharmacology, some of the newest heroes in the war against human disease are biologists and chemists working in chemical proteomics. Among the leaders in this research is the Novartis-Berkeley Center for Proteomics and Chemistry Technologies (NB-CPACT), a joint venture linking Novartis, a large pharmaceutical company, and the world’s leading public research university. Launched in October 2017, the center is developing new technologies to further the discovery of next-generation therapeutics for cancer and other diseases.
The discovery that carbon atoms act as a marker of time of death transformed everything from biochemistry to oceanography – but the breakthrough nearly didn’t happen. Martin Kamen had worked for three days and three nights without sleep. The US chemist was finishing off a project in which he and colleague Sam Ruben (B.S. ' Chem; Ph.D. '38, Chem), had bombarded a piece of graphite with subatomic particles. The aim of their work was to create new forms of carbon, ones that might have practical uses. Willard Libby (B.S. '31, Chem; Ph.D. '33, Chem) of Chicago University figured out that the radioactivity generated by carbon-14 could be exploited to tremendous advantage.
Researchers at the Department of Energy’s Lawrence Berkeley National Laboratory have developed a new separation method that is vastly more efficient than conventional processes, opening the door to faster discovery of new elements, easier nuclear fuel reprocessing, and, most tantalizing, a better way to attain actinium-225, a promising therapeutic isotope for cancer treatment.
A team of researchers, including faculty from Northwestern Engineering and UC Berkeley's College of Chemistry, has expanded the understanding of how virus shells self-assemble, an important step toward developing techniques that use viruses as vehicles to deliver targeted drugs and therapeutics throughout the body.
Frances Arnold admits it will be an emotional moment Friday when, as winner of the 2018 Nobel Prize in Chemistry, she’ll be the featured attraction at UC Berkeley for a Dean’s Dinner and reception at the College of Chemistry.
It was announced today that the 2019 Wolf Prize for Chemistry has been awarded to professors John F. Hartwig from University of California at Berkeley and Stephen L. Buchwald from MIT, for the development of efficient transition-metal catalysts that have revolutionized drug manufacturing, leading to breakthrough in molecule and synthetics design.
Zinc-zinc bonds are rare in chemistry. So are linear four-metal compounds. Nevertheless, Trevor D. Lohrey, a member of John Arnold’s group at the University of California, Berkeley, has made the first molecule with a Re-Zn-Zn-Re core. Lohrey used a rhenium(I) salt to reduce ZnCl2 and make a zinc cation to which anionic rhenium compounds coordinated.
Researchers at the Department of Energy’s Lawrence Berkeley National Laboratory have developed a new separation method that is vastly more efficient than conventional processes, opening the door to faster discovery of new elements, easier nuclear fuel reprocessing, and, most tantalizing, a better way to attain actinium-225, a promising therapeutic isotope for cancer treatment.
Frances Arnold admits it will be an emotional moment Friday when, as winner of the 2018 Nobel Prize in Chemistry, she’ll be the featured attraction at UC Berkeley for a Dean’s Dinner and reception at the College of Chemistry.
It was announced today that the 2019 Wolf Prize for Chemistry has been awarded to professors John F. Hartwig from University of California at Berkeley and Stephen L. Buchwald from MIT, for the development of efficient transition-metal catalysts that have revolutionized drug manufacturing, leading to breakthrough in molecule and synthetics design.
Zinc-zinc bonds are rare in chemistry. So are linear four-metal compounds. Nevertheless, Trevor D. Lohrey, a member of John Arnold’s group at the University of California, Berkeley, has made the first molecule with a Re-Zn-Zn-Re core. Lohrey used a rhenium(I) salt to reduce ZnCl2 and make a zinc cation to which anionic rhenium compounds coordinated.